Ally Bridge MedAlpha Master Fund L.P. 13D and 13G filings for Syros Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 7:02 pm Sale | 2023-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Ally Bridge MedAlpha Master Fund L.P. | 570,976 2.600% | -868,403 (-60.33%) | Filing |
| 2023-01-27 6:01 pm Purchase | 2022-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Ally Bridge MedAlpha Master Fund L.P. | 1,439,379 6.900% | 1,439,379 (New Position) | Filing |